|Mr. Brian Stuglik R.Ph., RPh||CEO & Director||890.32k||N/A||1959|
|Mr. Daniel W. Paterson||COO & Pres||679.82k||N/A||1961|
|Mr. Robert E. Gagnon||CFO & Chief Bus. Officer||586.64k||N/A||1974|
|Mr. Richard H. Aldrich M.B.A., Mba||Founder and Consultant||N/A||N/A||1954|
|Dr. Robert A. Weinberg||nder & Former Chair of Scientific Advisory Board||N/A||N/A||N/A|
|Dr. Piyush B. Gupta Ph.D.||Co-Founder||N/A||N/A||N/A|
|Dr. Michelle Dipp||Co-Founder||N/A||N/A||1976|
|Dr. Jonathan Pachter Ph.D.||Chief Scientific Officer||N/A||N/A||1958|
|Ms. Erin S. Cox||Sr. Director of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Mr. Sean C. Flynn||VP, Gen. Counsel & Sec.||N/A||N/A||1974|
Verastem, Inc., a biopharmaceutical company, focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being investigated in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), mesothelioma, and other solid tumors. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd. and CSPC Pharmaceutical Group Limited. The company was founded in 2010 and is based in Needham, Massachusetts.
Verastem, Inc.’s ISS Governance QualityScore as of December 2, 2020 is 8. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 7; Compensation: 7.